ABT-072 is a novel and potent nonnucleoside NS5B polymerase inhibitor and a candidate drug evaluated for treatment of hepatitis C virus (HCV).

Asunaprevir (formerly BMS-650032; BMS-650032; trade name in Japan and Russia: Sunvepra) is a potent and orally bioavailable small molecule inhibitor of the hepatitis C virus (HCV) NS3 (non-structural) protease that has been approved for use in Japan as part of a combination treatment for HCV infections. It inhibits HCV NS3 protease with an IC50 of […]

Balapiravir (also known as R1626 and Ro 4588161) is the tri-isobutyl ester prodrug of R1479 which is a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase. Balapiravir was developed to increase bioavailability and improve antiviral activity.

PSI-6206 13CD3 (RO-2433 13CD3; GS-331007 13CD3; Sofosbuvir metabolite GS-331007 13CD3) is the deuterium labeled form of PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 inhibits HCV replicon with EC90 of >100 μM. Sofosbuvir (also known as PSI-7977, GS-7977; trade names Sovaldi and Virunon) […]

PSI-7409 tetrasodium is a novel and active 5′-triphosphate metabolite of Sofosbuvir (PSI-7977). Sofosbuvir (also known as PSI-7977, GS-7977; trade names Sovaldi and Virunon) is a HCV NS5B polymerase inhibitor that is used for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir acts by inhibiting the RNA polymerase that the hepatitis C virus uses […]

Ledipasvir acetone (previously known as GS5885; GS-5885 acetone; Harvoni) is an HCV NS5A polymerase inhibitor with anti-HCV activity. It has been approved for for the treatment of hepatitis C virus (HCV) infection in combination with sofosbuvir (under the trade name of Harvoni for ledipasvir/sofosbuvir). Ledipasvir inhibits CV NS5A polymerase with EC50s of 34 pM and […]

Grazoprevir potassium salt (formerly known as MK-5172; brand name: Zepatier), the potassium salt form of grazoprevir, is a marketed anti-HCV drug acting as a selective inhibitor of the Hepatitis C Virus NS3/4A Protease with IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively. Grazoprevir received FDA approva as an […]

MK-0608 (MK608; 7-deaza-2′-C-methyladenosine; 7-DMA.) is a novel and potent anti-viral agent against HCV replication with an EC50 of 0.3 μM (EC90=1.3 μM) in the subgenomic-replicon assay.

Beclabuvir (formerly known as BMS-791325) is a novel, potent and non-nucleoside inhibitor of the HCV NS5B RNA polymerase, with nanomolar activity against HCV genotypes 1, 3, 4, 5 and 6 in vitro. It is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits […]

Simeprevir sodium, the sodium salt of simeprevir (previously known as TMC43), is a competitive, reversible, macrocyclic, noncovalent inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It acts directly against the hepatitis C virus and has been approved by the US FDA for use in combination with peginterferon-alfa and ribavirin to treat hepatitis C and […]